Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004049
Status:
COMPLETED
Last Update Posted:
2018-08-29
First Post:
1999-12-10
Brief Title:
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Phase I and Pharmacokinetic Study of SR-45023A Administered Once Every 7 Days
Status:
COMPLETED
Status Verified Date:
2001-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase I trial to study the effectiveness of SR-45023A in treating patients who have locally advanced or metastatic solid tumors that have not responded to previous treatment
PURPOSE Phase I trial to study the effectiveness of SR-45023A in treating patients who have locally advanced or metastatic solid tumors that have not responded to previous treatment
Detailed Description:
OBJECTIVES I Determine the maximum tolerated dose of SR-45023A in patients with locally advanced or metastatic solid tumors II Determine the quantitative and qualitative toxic effects of SR-45023A in these patients III Assess the plasma and urine pharmacokinetics of SR-45023A and relate these to drug effects if possible in these patients IV Determine any preliminary antitumor activity of SR-45023A in these patients
OUTLINE This is a dose escalation study Patients receive oral SR-45023A weekly Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity Cohorts of 3-6 patients receive escalating doses of SR-45023A until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity Patients are followed for up to 1 month
PROJECTED ACCRUAL A maximum of 36 patients will be accrued for this study
OUTLINE This is a dose escalation study Patients receive oral SR-45023A weekly Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity Cohorts of 3-6 patients receive escalating doses of SR-45023A until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity Patients are followed for up to 1 month
PROJECTED ACCRUAL A maximum of 36 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-V99-1560 | None | None | None |
| ILEX-SR102-A4 | None | None | None |
| SACI-IDD-99-06 | None | None | None |